|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The present study investigated the comparison between the cystatin C-based estimated glomerular filtration rate (GFRcys) and creatinine-based GFR (GFRcr) to determine whether these measurements are associated with CV biomarkers and elevated CVD risk in a general Japanese population.
|
31130557 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The underlying mechanisms by which cystatin C affects cardiovascular disease (CVD) are not very clear.
|
31317040 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cystatin C has been found as a new biomarker of cardiovascular disease.
|
31313057 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
We show that eGFRcys is most strongly associated with CVD and mortality, and, along with albuminuria, adds predictive discrimination to current CVD risk scores, whilst traditional creatinine-based measures are weakly associated with risk.
|
31700174 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
An imbalance in expression between cathepsins (such as cathepsins S, K, L, C) and their inhibitor cystatin C may favor proteolysis of ECM in the pathogenesis of cardiovascular disease such as atherosclerosis, aneurysm formation, restenosis, and neovascularization.
|
28978867 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This result suggests that an increase in cystatin C level could be a valuable surrogate marker for the risk of cardiovascular disease in patients with type 2 diabetes mellitus.
|
29090609 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Higher plasma levels of cystatin C were associated with non-obstructive CAD at coronary CTA in subjects with low-to-intermediate CVD risk and normal to mildly reduced kidney function.
|
28168796 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent studies have demonstrated that cystatin C is a valuable risk marker for cardiovascular disease morbidity and mortality.
|
30675144 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Serum cystatin C level is an early renal function marker and a cardiovascular disease predictor.
|
29442538 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cystatin C (CysC) is known to be related to cardiovascular disease (CVD), including the presence and severity of coronary artery disease (CAD) and future clinical events.
|
28749732 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Measurement of cystatin C may be useful for identifying women who are at high risk for cardiovascular disease.
|
28579260 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
To assess the association between cystatin C-based versus creatinine-based eGFR (eGFR cystatin C and eGFR creatinine, respectively) and cardiovascular risk using a modified PDAY risk score as a proxy for CVD in children and young adults.
|
28484878 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Using 14 year follow-up data on 9353 adults without a reported history of CVD from the Australian Diabetes, Obesity and Lifestyle study, we assessed the contributions of eGFR (assessed by cystatin C (eGFR<sub>cysC</sub> ) and serum creatinine (eGFR<sub>cr</sub> ) and albuminuria (uACR) to total and CVD mortality.
|
26938304 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Three hypotheses were tested: (1) higher levels of high-sensitivity cardiac troponin T, N-terminal of prohormone brain natriuretic peptide, and cystatin C predict risk of death, cardiovascular disease, HF, and dementia; (2) higher levels of cardiovascular disease biomarkers are associated with increased risk of HF and then secondary increased risk of dementia; and (3) risk of dementia is lower among participants with a combination of lower coronary artery calcium, atherosclerosis, and lower high-sensitivity cardiac troponin T (myocardial injury).
|
28735291 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cystatin C is an established marker of kidney function and an emerging biomarker for CVD events.
|
27856090 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition to GFR, cystatin C serum concentration is positively and independently associated with CCIMT in patient with URHT phenotype and subclinical CVD.
|
27876431 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Increased serum cystatin C levels are related to the prognosis of cardiovascular diseases.
|
29254149 |
2017 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Mendelian randomization analyses did not support a causal role of cystatin C in the etiology of CVD.
|
27561768 |
2016 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The phenotypic correlation between Cystatin C and CVD correlation was 0.16 (0.12 to 0.20) in men and 0.17 (0.13 to 0.21) in women, whereas the genetic correlation in males was 0.41 (0.21 to 0.62) while it was non-significant in females.
|
25589536 |
2015 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Adjusting for this genetic effect on cystatin C concentrations may improve GFR estimation, reclassify cases of chronic kidney disease (CKD), and strengthen risk estimates for cardiovascular disease (CVD) and mortality.
|
23932088 |
2014 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Although matrix metalloproteinases and serine proteases participate in these pathological events, the discovery of cysteine protease cathepsins, such as cathepsins K, S, L, and B, and cystatin C, and their tissue distribution has suggested that at least some of them participate in cardiovascular disease.
|
21986502 |
2011 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
Cystatin C has been accepted to be a significant prognostic factor for cardiovascular diseases.
|
21356263 |
2011 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The lower mass of PON1, an anti-inflammatory HDL-associated enzyme, in T2DM with cystatin C-eGFR <60 ml/min per 1.73 m(2) may contribute to their increased risk for cardiovascular disease.
|
19151417 |
2009 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Multivariable logistic regression was used to evaluate the association between CVD risk factors and high CysC (CysC > or =95(th) percentile cut-point).
|
18940290 |
2008 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The potential significance of imbalance in expression between cathepsins and their inhibitor cystatin C in cardiovascular disease has been highlighted by the demonstration of cystatin C deficiency in human atherosclerosis and abdominal aortic aneurysms.
|
14726415 |
2004 |